MYH9-related platelet disorders
- PMID: 19408192
- DOI: 10.1055/s-0029-1220327
MYH9-related platelet disorders
Abstract
Myosin heavy chain 9 (MYH9)-related platelet disorders belong to the group of inherited thrombocytopenias. The MYH9 gene encodes the nonmuscle myosin heavy chain IIA (NMMHC-IIA), a cytoskeletal contractile protein. Several mutations in the MYH9 gene lead to premature release of platelets from the bone marrow, macrothrombocytopenia, and cytoplasmic inclusion bodies within leukocytes. Four overlapping syndromes, known as May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, and Sebastian platelet syndrome, describe different clinical manifestations of MYH9 gene mutations. Macrothrombocytopenia is present in all affected individuals, whereas only some develop additional clinical manifestations such as renal failure, hearing loss, and presenile cataracts. The bleeding tendency is usually moderate, with menorrhagia and easy bruising being most frequent. The biggest risk for the individual is inappropriate treatment due to misdiagnosis of chronic autoimmune thrombocytopenia. To date, 31 mutations of the MYH9 gene leading to macrothrombocytopenia have been identified, of which the upstream mutations up to amino acid approximately 1400 are more likely associated with syndromic manifestations than the downstream mutations. This review provides a short history of MYH9-related disorders, summarizes the clinical and laboratory characteristics, describes a diagnostic algorithm, presents recent results of animal models, and discusses aspects of therapeutic management.
Similar articles
-
[Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].Rinsho Byori. 2009 Apr;57(4):365-70. Rinsho Byori. 2009. PMID: 19489439 Review. Japanese.
-
Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome).Eur J Haematol. 2007 Sep;79(3):263-8. doi: 10.1111/j.1600-0609.2007.00913.x. Epub 2007 Jul 26. Eur J Haematol. 2007. PMID: 17655694
-
MYH9 related platelet disorders - often unknown and misdiagnosed.Klin Padiatr. 2011 May;223(3):120-5. doi: 10.1055/s-0031-1275664. Epub 2011 May 12. Klin Padiatr. 2011. PMID: 21567368 Review.
-
Haematological characteristics of MYH9 disorders due to MYH9 R702 mutations.Eur J Haematol. 2007 Mar;78(3):220-6. doi: 10.1111/j.1600-0609.2006.00806.x. Epub 2007 Jan 16. Eur J Haematol. 2007. PMID: 17241369
-
Clinical manifestation and molecular genetic characterization of MYH9 disorders.Platelets. 2009 Aug;20(5):289-96. doi: 10.1080/09537100902993022. Platelets. 2009. PMID: 19557653
Cited by
-
Potential Biomarkers of Acute Ischemic Stroke Etiology Revealed by Mass Spectrometry-Based Proteomic Characterization of Formalin-Fixed Paraffin-Embedded Blood Clots.Front Neurol. 2022 Apr 19;13:854846. doi: 10.3389/fneur.2022.854846. eCollection 2022. Front Neurol. 2022. PMID: 35518205 Free PMC article.
-
Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15.Hum Mol Genet. 2010 May 1;19(9):1805-15. doi: 10.1093/hmg/ddq039. Epub 2010 Feb 2. Hum Mol Genet. 2010. PMID: 20124285 Free PMC article.
-
MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations.Hum Mutat. 2014 Feb;35(2):236-47. doi: 10.1002/humu.22476. Epub 2013 Dec 12. Hum Mutat. 2014. PMID: 24186861 Free PMC article.
-
Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders.Mol Genet Genomic Med. 2014 Jul;2(4):297-312. doi: 10.1002/mgg3.68. Epub 2014 Feb 7. Mol Genet Genomic Med. 2014. PMID: 25077172 Free PMC article.
-
Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg(2+) homeostasis and cytoskeletal architecture.Nat Commun. 2016 Mar 29;7:11097. doi: 10.1038/ncomms11097. Nat Commun. 2016. PMID: 27020697 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous